G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
93 hedge funds and large institutions have $457M invested in G1 Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 42 increasing their positions, 17 reducing their positions, and 14 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 17
3% more call options, than puts
Call options by funds: $183K | Put options by funds: $178K
0% more funds holding
Funds holding: 93 → 93 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
13% less capital invested
Capital invested by funds: $525M → $457M (-$68.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$6.89M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
+$4.57M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.65M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$21.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$19M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$5.72M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.97M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$2.58M |
GTHX Hedge Fund Activity: Q1 2019 in Review
93 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q1 2019, worth a combined $457M — down 13% from $525M a quarter earlier.
Fund positioning in GTHX was balanced in Q1 2019: 14 funds opened new positions, 14 closed out, 42 added to existing stakes and 17 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $16.4M. The largest seller was Capital World Investors, cutting an estimated $21.3M.
- 93 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $457M of G1 Therapeutics, Inc. Common Stock stock for Q1 2019, down 13% quarter-over-quarter.
- 14 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q1 2019 and 14 closed out, a net change of 0 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q1 2019 was Wellington Management Group, an estimated $16.4M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q1 2019 was Capital World Investors, an estimated $21.3M sold.
Based on aggregated 13F filings for Q1 2019.